CSOP Hang Seng Biotech ETF(03174.HK) Jumps 3.84% in Early Trading at HK$2.976
NewTimeSpace News: As at 10:05 on June 24, 2026, CSOP Hang Seng Biotech ETF(03174.HK) gained 3.84% to HK$2.976. The ETF traded 3,978,800 units with a total turnover of HK$11.753 million and an average traded price of HK$2.954. Its current net asset value per unit is HK$2.877, total assets under management stand at HK$730 million, and one trading lot consists of 100 units.
CSOP Hang Seng Biotech ETF(03174.HK) tracks the Hang Seng Biotechnology Index. This index focuses on leading biotechnology companies listed in Hong Kong, covering segments including innovative drugs, CXO services, vaccines, gene therapy and other related sectors.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSOP Biotech(03174.HK) up 3.22%, Hengrui Novo license up to $2.6bn
- HK shares ETFs Daily Report: ChinaAMC Innovative Drugs Leads Gains; Biotech and Semiconductors Strengthen, Hang Seng TECH Retreats — September 29, 2026
- CSOP Biotech(03174.HK) up 2.89%, AstraZeneca $2bn Akeso partner deal
- CSOP Hang Seng Biotech ETF (03174.HK) Rises 4.84% Intraday after Ten Departments Issue the Pharmaceutical Industry 15th Five-Year Plan, Targeting 20%+ Annual Growth for Innovative Drugs
- CSOP Hang Seng Biotech ETF (03174.HK) up 4.79% intraday on policy catalysts